Results from a Phase 1 clinical trial of Cytogen Corporation (Nasdaq: CYTO)’s QUADRAMET® (samarium Sm-153 lexidronam injection) in combination with hormonal therapy and external beam radiation therapy in high-risk, clinically non-metastatic prostate cancer patients, demonstrated positive results.
QUADRAMET® is Cytogen Corp.’s oncology product indicated for the relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan.
The said clinical data revealed that the combination regimen was well tolerated with preliminary anti-tumor activity observed as evidenced by prostate specific antigen or PSA responses.
According to Richard Valicenti, M.D., associate professor of radiation oncology at Jefferson Medical College of Thomas Jefferson University and Jefferson's Kimmel Cancer Center in Philadelphia:
"The strategy is to use QUADRAMET, a bone-targeted agent, upfront and in combination with standard treatment regimens consisting of a combination of hormones and external beam radiation for high-risk prostate cancer.
We're hypothesizing that the combination of hormones and radiation could be used to treat microscopic bony metastasis, which could help reduce death rates due to prostate cancer."
These results were presented (Abstract #2238) at the (ongoing, November5-9, 2006) 48th annual meeting of the American Society for Radiology and Oncology (ASTRO) held in Philadelphia.
Find more details from the press release.
Comment Preview